Skip to main content

Table 2 Changes in KINDL-R patient-rated scale from baseline to endpoint (last observation carried forward)

From: Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination

KINDL-R domains OFC Placebo Between-group p valuea
N Mean baseline (SD) LS mean change (SE) N Mean baseline (SD) LS mean change (SE)
Total 107 51.2 (15.6) 12.8 (1.7) 40 45.2 (13.2) 7.9 (2.4) 0.050
Physical well-being 151 54.9 (20.1) 12.8 (2.2) 70 54.4 (20.4) 12.4 (2.8) 0.873
Emotional well-being 150 53.3 (22.9) 13.7 (2.1) 70 51.0 (23.3) 11.1 (2.7) 0.330
Self-esteem 150 36.9 (26.7) 18.2 (2.7) 69 32.3 (20.9) 10.7 (3.4) 0.028
Family 147 58.2 (21.1) 9.6 (2.0) 68 55.5 (21.6) 9.6 (2.6) 0.994
Friends 147 52.8 (25.0) 14.8 (2.5) 62 47.9 (24.6) 12.2 (3.2) 0.427
School 110 46.9 (17.8) 6.5 (2.3) 44 46.6 (17.5) 4.6 (3.3) 0.559
Disease 10 41.7 (14.6) 12.3 (7.2) 3 36.1 (27.7) −9.8 (13.6) 0.152
  1. KINDL-R KINDL questionnaire for measuring health-related quality of life in children and adolescents, LS least squares, N number of patients, OFC olanzapine/fluoxetine combination, SD standard deviation, SE standard error
  2. aDifference between LS mean change scores